Idera Pharmaceuticals acquires biotech firm with pipeline of orphan drugs, takes on new CEO


Following the acquisition, the combined company has cash on hand of about $27 million, which provides a runway into the third quarter of 2023.

Previous Durham CEO now leads public company following acquisition
Next Homewood Mediterranean restaurant, market closing